^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Solid Tumor
    Drug:IAH0968 (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A phase II/III clinical trial evaluating IAH0968, with or without CAPEOX, for HER2-expressing advanced/metastatic solid tumors and gastric cancer (Note: currently in phase II).

    Excerpt:
    ......
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A study of IAH0968 in combination with gemcitabine and cisplatin for the treatment of HER2-positive unresectable advanced/metastatic malignancies and cholangiocarcinoma.

    Excerpt:
    ......
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer

    Excerpt:
    ...Proof of HER2-positive (IHC) 3+, or IHC 2+ and FISH +, by immunohistochemical (IHC) staining and/or fluorescence in situ hybridization (FISH), and wild type KRAS, NRAS, and BRAF genes....
    Trial ID:
    NCT05673512
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

    Excerpt:
    ...The participant should have been diagnosed with HER2-positive advanced solid tumors that have failed standard treatment, as confirmed by pathological histology or cytology....
    Trial ID:
    NCT05991518
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive, heavily pretreated solid tumors: Results from a phase Ⅰa/Ⅰb, first-in-human, open-label, single-center study.

    Published date:
    05/25/2023
    Excerpt:
    In heavily pretreated metastatic pts with HER2 positive, IAH0968 demonstrated promising clinical activity and tolerable safety profiles.
    DOI:
    10.1200/JCO.2023.41.16_suppl.e15098
    Trial ID:
    NCT04934514